- Study demonstrates the efficacy of AI in both baseline and follow-up lung cancer screening.
- AI achieves 100% detection rate for reference positive cancers in 3-month follow-up scans.
- Significant reduction in false-positive rates: 7.8% at 3 months and 0.9% at 12 months.
- Findings support the potential for AI to improve the efficiency and cost-effectiveness of national lung cancer screening programs.
Coreline Soft, a leading medical artificial intelligence (AI) company, announced today that a joint study on lung cancer screening conducted in collaboration with iDNA, Erasmus MC, and the University of Groningen has been published in the prestigious European Journal of Cancer (EJC). The study validates the effectiveness of AI-based lung cancer screening technology across both baseline and follow-up examination stages.
A key focus of this research was to analyze the AI's ability to accurately detect lung cancer progression in subsequent follow-up examinations (e.g., at 3 months and 12 months), going beyond single-time-point image interpretation. This area is directly linked to the operational structure of actual national lung cancer screening programs, making the findings highly significant from both clinical and policy perspectives.
The study results showed that Coreline Soft's AI lung cancer screening solution, AVIEW LCS, achieved a 100% detection rate for reference positive cancers in 3-month follow-up scans. Notably, the AI identified small, fast-growing cancers under 100mm³, which were initially classified as 'under observation' due to their size below the threshold in the baseline scan, at an earlier stage than conventional interpretation methods.
This performance is attributed to AVIEW LCS's ability to precisely calculate nodule volume changes and Volume Doubling Time (VDT), automatically tracking risk signals. The study evaluated the AI as demonstrating analysis performance with high consistency and reproducibility compared to reader-centric follow-up methods.
The reduction in false-positive rates is another noteworthy achievement. According to the research, the false-positive rate decreased to 7.8% in 3-month follow-up scans and further to 0.9% in 12-month follow-ups. These findings serve as evidence that AI can lead to reduced unnecessary follow-up imaging and observation, resulting in medical resource savings and improved management efficiency for screening participants in national-level lung cancer screening programs.
Coreline Soft explained that these research results align with the trend of expanding national lung cancer screening programs across Europe. The company has been supplying its AI solutions to major projects such as Europe's '4ITLR', Germany's 'HANSE', Italy's 'RISP', and France's 'IMPULSION'. In Germany and other countries, Coreline Soft has contributed to the discussion and adoption of AI-based quantitative analysis as a recommended direction for primary reading in lung cancer screening.
The industry views Coreline Soft's accumulated technical reliability and actual operational experience as key competitive advantages for future global market share expansion, especially as lung cancer screening gains momentum in Europe. Technology capable of providing consistent judgment across follow-up examination stages, beyond single-time-point reading, is evaluated as a critical factor determining the operational efficiency and sustainability of national screening programs.
"This study is a case that proves AI can contribute to all three key indicators in lung cancer screening: improved early detection rates, enhanced screening efficiency, and budget savings," said Lee Jae-yeon, CTO and Co-founder of Coreline Soft. "We plan to expand the utilization of AVIEW, centering on major European countries, and further strengthen our overseas sales growth through global partnerships."
December 16, 2025
List